amyotrophic lateral sclerosis

Apr 05, 2022

FDA Approves Yescarta as a First CAR T-cell Therapy for Initial Treatment of R/R Large B-cell Lymphoma Until now, existing CAR-T therapies have been reserved for patients with blood cancer who have tried multiple treatments. The FDA has approved Yescarta, a CD19-directed CAR-T therapy developed by Gilead Science...

Sep 16, 2021

FDA’s Go-Ahead to Amylyx New Drug Application for ALS Drug  Amylyx Pharmaceuticals has announced its plan to submit a New Drug Application (NDA) to the U.S. FDA for its drug, AMX0035 (sodium phenylbutyrate (PB) and Taurursodiol (TURSO)), for the treatment of Amyotrophic lateral sclerosis (ALS).  A f...

Aug 24, 2021

AstraZeneca's Newly Occupied Alexion Hits Rock Bottom After Ultomiris (Ravulizumab) Fails to Show Efficacy in Patients with Amyotrophic Lateral Sclerosis AstraZeneca's 39 billion USD complete acquisition of Alexion took over just a few months back. Unpleasant news strike hard for their first deal in the rare neu...

Feb 26, 2021

CNS disorders are a wide-ranging set of disorders in which the brain loses its normal functioning, limiting everyday ability to function. These may arise from various reasons-some are inherited, some result from damage, and some from infections. It contributes to the highest disability-adjusted life years. The curr...

Dec 25, 2020

Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. The disease progresses over 3–5 years, making voluntary movements of arms and legs impossible. I...

Jul 02, 2020

Amylyx Pharmaceuticals grabs USD 30 Million  Amylyx Pharmaceuticals has grabbed USD 30 million boosts after posting positive data, which showed it could help decrease amyotrophic lateral sclerosis (ALS). AMX0035, which is its leading candidate, is being tested in degenerative ALS and Alzheimer’s disease....

Jun 25, 2020

Regeneron recognizes new combos to boost I-O drug Libtayo's cancer response PD-1/L1 inhibitors work by enhancing the immune response to cancer, have benefitted patients combat several types of tumors. However, many people either do not respond to these checkpoint inhibitors, or they eventually develop resistance...

Oct 11, 2018

Streamlined solutions provided by Cognitive Clinical Trials (CCT) related to the treatment and prevention of Alzheimer’s disease Congnitive Clinical Trials (CCT) has introduced a new research model that prevail over the top obstacles being faced by the researchers related to the treatment and prevention of Alzheime...

Mar 28, 2018

Novo Holdings optimistic about investments in life sciences Novo Holdings is planning to increase its investment in early & late stage biotechs. Its focus will be mainly in the U.S. and Europe. They are optimistic about the investment in life-science companies with their past experience. NMD gets USD 47 million...

Jan 30, 2018

Spasticity is defined as a condition in which certain muscles are continuously contracted, resulting in stiffness or tightness of the muscles, which interferes with normal movement, speech and gait. It is also known as a motor disease which is characterized by a velocitydependent increase in tonic stretch reflexes w...